Login / Signup

Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited.

Amina BensalemDenis MullemanGilles PaintaudNicolas AzzopardiValérie Gouilleux-GruartDivi CornecUlrich SpecksDavid Ternant
Published in: Clinical pharmacokinetics (2021)
A non-linear target-mediated elimination of rituximab was detected in AAV patients. Our PK-PD model allowed quantification of the association between rituximab concentrations and ANCA levels. This decrease was deep but delayed, and more sustained in patients with MPO-ANCA than in those with PR3-ANCA. Our results suggest that repeating courses of rituximab might improve the clinical response to rituximab.
Keyphrases
  • diffuse large b cell lymphoma
  • chronic lymphocytic leukemia
  • hodgkin lymphoma
  • end stage renal disease
  • newly diagnosed
  • clinical trial
  • patient reported outcomes
  • phase ii